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Abstract 
Polymeric microneedle (MN) arrays continue to receive growing attention due to their ability 
to bypass the skin’s stratum corneum barrier in a minimally-invasive fashion and achieve 
enhanced transdermal drug delivery and “targeted” intradermal vaccine administration. In 
this research work, we fabricated biodegradable bilayer MN arrays containing nano - 
microparticles for targeted and sustained intradermal drug delivery. For this study, model 
drug (vitamin D3, VD3)-loaded PLGA nano- and microparticles (NMP) were prepared by a 
single emulsion solvent evaporation method with 72.8% encapsulation of VD3.  The prepared 
NMP were directly mixed 20% w/v poly(vinyl pyrrolidone) (PVP) gel, with the mixture filled 
into laser engineered micromoulds by high-speed centrifugation (30 min) to concentrate 
NMP into MN shafts. The particle size of PLGA NMP ranged from 300 nm to 3.5 µm and 
they retained their particle size after moulding of bilayer MN arrays. The relatively wide 
particle size distribution of PLGA NMP was shown to be important in producing a compact 
structure in bilayer conical, as well as pyramidal, MN, as confirmed by scanning electron 
microscopy. The drug release profile from PLGA NMP was tri-phasic, being sustained over 5 
days. The height of bilayer MN arrays was influenced by the weight ratio of NMP and 20% 
w/v PVP. Good mechanical and insertion profiles (into a skin simulant and excised neonatal 
porcine skin) were confirmed by texture analysis and optical coherence tomography, 
respectively. Ex vivo intradermal neonatal porcine skin penetration of VD3 NMP from bilayer 
MN was quantitatively analysed after cryostatic skin sectioning, with 74.2 ± 9.18% of VD3 
loading delivered intradermally. The two-stage novel processing strategy developed here 
provides a simple and easy method for localising particulate delivery systems into dissolving 
MN. Such systems may serve as promising means for controlled transdermal delivery and 
targeted intradermal administration. 
 
Keywords: Microneedles, Bilayer, PLGA, Nanoparticles, Microparticles, Vitamin D3  
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1. Introduction 
Transdermal drug delivery is a useful approach for administration of therapeutic molecules, 
as it bypasses first-pass metabolism associated with oral administration [1]. However, the 
molecules which can be delivered via the transdermal route are restricted to small (<500 Da) 
and moderately hydrophobic agents, due to the stratum corneum, which is the foremost 
barrier to systemic absorption of topically-applied drugs [2-4]. To improve delivery across 
the stratum corneum, a range of physical enhancement methods have been developed, 
including iontophoresis [4], ultrasound [5], liquid jet injection [6], gene guns [7], laser [8] 
and electroporation [9], all with relatively limited success [10]. Micron-scale needles (10 µm 
-900 µm), called microneedles (MN) [11, 12], represent a much more promising approach. 
MN are minimally-invasive, pain-free devices capable of penetrating the skin’s stratum 
corneum, thereby overcoming its barrier properties [13]. Therefore, MN platforms can 
potentially provide rapid or controlled transdermal delivery for an increased number of 
therapeutic molecules [14]. MN technology is, at last, realizing its early promise, with human 
trials recently conducted for the delivery of vaccines using dissolving MN patches [15].  
There is a now the possibility to deliver molecules as a bolus dose using rapidly-dissolving 
MN and also to achieve longer-term controlled transdermal delivery through encapsulation of 
drugs prior to MN formulation or direct loading into biodegradable MN. For such sustained 
delivery applications, MN patches may need to remain inserted in skin for hours or even 
days. Such prolonged insertion times could cause as-yet unseen problems. To prevent this, 
several approaches have been developed for long-term controlled transdermal delivery, 
including the use of solid MN to generate physical pores in stratum corneum prior to topical 
application of controlled release particle suspensions or rapid delivery of drug-loaded 
polymer particles into the skin by dissolving microneedle arrays. Considering the pore sized 
generated by MN puncture, as well as the area of the stratum corneum typically treatable 
using conventional MN patches, achieving a clinically-relevant effect would be difficult to 
achieve for all but the most potent therapeutic agents [16]. Improved designs could enhance 
patient care. 
Dissolving polymeric MN are a potential choice for targeted transdermal and intradermal 
delivery because of their simple and readily-scalable fabrication and low cost [17]. Recently, 
dissolving MNs have proved to augment transdermal and intradermal delivery of a variety of 
hydrophilic molecules, particularly bio-macromolecules [18]. 
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Various biodegradable and water-soluble polymers have been used to fabricate dissolving 
MN arrays for rapid drug delivery [19]. However, developing biodegradable nano-
microparticles loaded dissolving MN arrays, in which the release rate could be controlled 
may be useful for a variety of molecules [20].  
Poly(lactic-co-glycolic acid) (PLGA) is the most explored polymer for nanoparticle and 
microparticle design for targeted and controlled drug delivery systems due to its 
biodegradability and good biocompatibility [21]. PLGA carriers provide controlled drug 
release from periods of a few days up to several months based on their molecular weight and 
ratio of lactide: glycolide chains. PLGA degrades into water-soluble, non-toxic, products 
through hydrolysis in-vivo. Indeed, several PLGA microparticle-based products, such as 
Lupron Depot®, are currently approved for human use [22].  
In this paper, we present a simple yet innovative technique to prepare two-layered MN arrays 
to improve the intradermal delivery of nanoparticles and microparticles. For this purpose, 
vitamin D3 (VD3) was selected as a model drug. First, VD3 was encapsulated within PLGA 
nano-microparticles (NMP) by an emulsion solvent evaporation method. NMP were 
characterised for particle size, encapsulation efficiency and release profile and, subsequently, 
loaded inside the needle tips of MN arrays by single-step centrifugation. The developed 
bilayer MN system was tested for ex-vivo intradermal neonatal porcine skin penetration by 
optical coherence tomography and cryostat microtome skin sectioning and drug deposition 
was quantified. 
2. Materials & methods 
2.1. Materials 
Vitamin D3, D-α-tocopherol succinate and PLGA Resomer 752H (molecular ratio of D,L-
lactide/glycolide 75/25, Mw 9850 g/mol), poly(vinylpyrrolidone) (PVP, MW 360,000 g/mol) 
and poly(vinyl alcohol) (PVA, MW 10000 g/mol), acetonitrile and methanol (both of HPLC 
grade) were all purchased from Sigma-Aldrich (Poole, Dorset, UK). Parafilm M@, a flexible 
thermoplastic sheet (127 µm thickness) made of olefin-type material and used as a skin 
simulant for insertion studies, was obtained from BRAND GMBH (Wertheim, Germany). All 
other chemicals used were of analytical grade. Millipore HPLC-grade water was used 
throughout the study. 
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2.2. Preparation of PLGA nano-microparticles 
PLGA NMP were prepared using an oil-in-water (O/W) emulsion solvent evaporation 
method. Briefly; PLGA (100 mg) and model drug, VD3 (25 mg) with stabiliser, tocopherol 
succinate (TS) (10 mg), were dissolved in 1 ml of methylene chloride (DCM). This organic 
phase was added into 3 ml cooled double distilled water containing 2% w/v PVA, with or 
without 5% w/v mannitol. The resulting mixture was subjected to homogenisation at 18,000 
rpm for 60 sec using a high-speed homogenizer (Yellowline ID18 Basic, IKA, Brazil) in 
order to produce a stable o/w emulsion with diminished droplet size. The organic solvent was 
then removed by evaporating under magnetic stirring for 3 h at room temperature to yield 
solid NMP. The particle size was measured using a Mastersizer 3000 (Malvern, Worcester, 
UK). To check entrapment efficiency and other solid state characteristics of the prepared 
NMP, the entire dispersion was centrifuged at 11,000 rpm for 10 min using a high-speed 
centrifuge in three cycles and the sediment constituting NMP was removed. NMP were then 
pre-frozen (-70 °C) for 12 h and subsequently lyophilized for 8 h with hold and ramp cycles 
from -40 °C to 25°C. 
2.3. Fabrication of PLGA particles loaded dissolving bilayer microneedles 
The fabrication of MN arrays containing PLGA NMP is summarised in Figure 1. Briefly, 
NMP in 2% w/w PVA were mixed with equal weights of 20% w/v aqueous solution of PVP 
(Mw ̴ 360 kDa) and approximately 500 mg of this mixture was poured into laser-engineered 
silicone conical (19×19 and 12×12 arrays) as well as master-templated pyramidal (14×14 
arrays) micromould templates [17]. All these moulds showed needle heights of 600 µm and 
widths at base of 300 µm. The moulds were centrifuged at 2913×g for 30 min and then 
allowed to dry under ambient condition for 48 hours. To optimize the NMP concentration in 
needles of the dissolving MN array, different weight ratios of NMP and 20% w/v PVP were 
investigated, as summarized in Table 1. MN arrays were then removed from the moulds and 
assessed for needle formation and mechanical strength.  For use as a control in permeation 
studies, MN-free control patches were prepared by the same method, except using 
micromoulds with no indentations. 
2.4.Particle characterisation 
Particle size and polydispersity of NMP before and after MN formulation were evaluated on 
the Mastersizer 3000. Around 20 mg of hydrated NMP were suspended in deionized water 
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and stirred at 1700 rpm. In order to determine particle size, each sample was measured 6 
times. The dispersant and particle refractive index (RI) were 1.33 and 1.59, respectively. 
Similarly, the particle size of NMP was measured after incorporating into MN arrays by 
dissolving the arrays in 15 ml phosphate-buffered saline (pH 7.4). Subsequently, 5 ml of this 
solution was added into 500 ml of distilled water and the particle size was measured. 
2.5. Drug content analysis 
The content of the VD3 in the PLGA NMP was determined by disruption of accurately 
weighed 5 mg NMP using 0.2 ml of acetonitrile. After dissolving NMP in acetonitrile by 
vortexing, 0.8 ml methanol was added to precipitate the PLGA polymer while VD3 remained 
soluble in the acetonitrile-methanol mixture. The disrupted NMP solution was then 
centrifuged at 10,000 rpm for 5 minutes and the total VD3 content was determined using 
HPLC (see Section 2.7). The percentage of the VD3 entrapped was calculated as follows: 
Entrapment efficiency (%) =  
Amount of drug entrapped  
Total amount  of drug taken
  x 100 Eq. 1  
 
To determine total content VD3 in bilayer MN arrays, only tips of MN arrays without 
baseplate were removed carefully using a scalpel and placed into Eppendorf tubes to 
determine VD3 content as per the above procedure. These experiments performed in 
triplicate.      
2.6. In-vitro release of drug from PLGA NMP 
Accurately 15 mg of freeze-dried PLGA NMP were placed in a 2 ml microcentrifuge tube 
and suspended in 1 ml of 10 mM PBS pH 7.4 with 1% w/v Tween 80 [23]. This mixture was 
kept under stirring at 50 rpm in a waterbath shaker at 37 ± 2ºC. At predetermined time 
intervals, samples were collected and centrifuged at 3000 rpm for 5 min. Aliquots of 1 ml 
supernatant were taken and replaced with an equal volume of fresh release medium. The 
supernatant was centrifuged at 10,000 rpm for 10 min. The amount of drug in the collected 
supernatant was measured by HPLC. All release tests were performed in triplicate over 7 
days. 
2.7. Pharmaceutical Analysis 
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Quantiﬁcation of VD3 was performed using reversed-phase HPLC (Agilent 1200
® Binary 
Pump, Agilent 1200®, Standard Autosampler, Agilent 1200® Variable Wavelength Detector; 
Agilent Technologies UK Ltd., Stockport, UK). Chromatographic separation was achieved 
using a Luna C18 (ODS1) column (150 × 4.6 mm
2 i.d. with 5 µm packing; Phenomenex, 
Macclesﬁeld, UK) with isocratic elution and UV detection at 265 nm. The mobile phase was 
a mixture of acetonitrile: methanol: water (90:08:02 v/v/v) with a run time of 8 min. The 
column temperature was 20°C and the injection volume was 20 µL. The chromatograms 
obtained were analysed using Agilent ChemStation Software B.02.01.  
2.8. Microscopy analysis of MN arrays 
Surface morphology of PLGA NMP-loaded MN arrays was evaluated by using optical and 
scanning electron microscopy. A Keyence VHX-700F Digital Microscope (Keyence, Osaka, 
Japan) and a TM3030 benchtop scanning electron microscope (SEM) (Hitachi, Tabletop 
Microscope, Europe) were used. The latter was used in low vacuum mode at a voltage of 15 
kV.  
2.9. Mechanical and insertion properties of NMP loaded MN arrays 
To assess the compression and insertion properties of the bilayer MN arrays, a mechanical 
test was conducted using a TA-XT2 Texture Analyser (Stable Microsystems, Haslemere, 
UK) in compression mode, as described previously [24]. To test compression, the initial 
heights of bilayer MN arrays were first determined by using a stereomicroscope. Then, 
bilayer MN arrays were attached with the help of double-sided adhesive tape to the movable 
cylindrical probe of the Texture Analyser and pressed by the test station against a ﬂat 
aluminium block at a rate of 1.19 mm/s for 30 s and a force of 32 N. These force conditions 
approximately replicate the average conditions of patients applying MN arrays, as described 
previously [25]. 
Bilayer MN heights were measured again using the stereomicroscope and the percentage 
reductions in height following the application of the axial compression load were calculated.  
To determine insertion properties, Paraﬁlm M® was used as per previously validated insertion 
model [26]. The initial heights of the bilayer MN arrays were measured microscopically prior 
to this test. The Paraﬁlm M® sheet was folded into an eight-layer ﬁlm (approximately 1 mm 
thickness). Following attachment of the MN array to the movable probe of the Texture 
Analyser, the probe was lowered onto the folded Paraﬁlm M® at a speed of 1.19 mm/s until 
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the required force of 32 N was exerted and held for 30 s. The MN were then removed from 
the Parafilm M® sheet after insertion, the sheet unfolded and the number of holes in each 
layer and MN heights evaluated using a Leica EZ4 D digital microscope (Leica, Wetzlar, 
Germany). 
 
2.10. Optical Coherence Tomography 
Eight layers of Parafilm M® (≈1 mm thickness) was used as a skin simulant for MN insertion 
studies. Neonatal porcine full-thickness skin was also used to check insertion of NMP loaded 
MN tips. MN arrays were inserted using the Texture Analyser, with force of 32 N for 30 s. 
Optical coherence tomography (OCT) images were recorded using an EX1301 OCT 
Microscope (Michelson Diagnostics Ltd., Kent, UK). 
2.11. Ex-vivo deposition studies in excised porcine skin 
Ex-vivo deposition of VD3 loaded PLGA NMP containing bilayer MN was performed in the 
excised porcine skin as per previously reported procedures [27]. In detail, the receptor 
compartment of standard jacketed Franz-type diffusion cell was ﬁlled with degassed PBS pH 
7.4 and was thermostatically controlled at 37 °C.  Full thickness neonatal porcine skin was 
excised from stillborn piglets, shaved and pre-equilibrated in PBS pH 7.4 for 1 h before 
beginning the experiments. A circular specimen of the skin was secured to the donor 
compartment of the diffusion cell using cyanoacrylate adhesive with the stratum corneum 
side facing the donor compartment. Bilayer MN arrays were inserted using manual pressure. 
MN-free control patches were similarly applied. After 6 h of the application period, the skin 
sample was removed and separated from the MN array. The surface of the specimen was 
carefully wiped with a damp tissue to remove any traces of the formulation. A circular-
shaped scalpel was used to excise the tissue exposed to the MN array, which was then ﬂash 
frozen in a liquid nitrogen atmosphere prior to tissue sectioning. Sections of frozen tissue 
were fixed on the stage of a cryostatic microtome (Leica CM1900-1-1 cryostatic microtome, 
Leica Microsystems, Nussloch, Germany) using tissue embedding ﬂuid. The microtome 
environment and stage were operated at -25 °C.  Frozen tissue sections were positioned so 
that their upper surfaces, to which patches had been attached, were parallel to the sliding 
motion of the blade. Slice thickness was set at 50 µm and 4 consecutive slices were taken and 
placed into 1.5 ml Eppendorf tubes. This procedure was repeated until the entire section was 
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sliced. The total depth of slicing into the tissue was approximately 1.5 mm. To the Eppendorf 
tubes, 1 ml of acetonitrile was added and sonicated for 30 min. Samples were then 
centrifuged at 10,000 rpm for 5 min and the supernatant containing extracted drug was 
collected and quantiﬁed using HPLC. 
2.12. Statistical analysis 
The results are presented as means ± standard deviation (SD) of the mean. Statistical 
comparison between bilayer MN and control patches, in terms of depth penetration, were 
made using the Mann-Whitney U-test by using GraphPad Prism software (ver. 6; GraphPad, 
Inc., San Diego, USA). A difference of p < 0.05 was considered to be statistically significant. 
3. Results 
3.1 Characterisation of VD3 loaded PLGA NMP 
In this study, the PLGA NMP were prepared using a single emulsion method. Particle size 
was found to range from nano to micron scale, with a relatively wide particle size 
distribution, as shown in Figure 2. Particle size of MP prepared with mannitol (D 10: 386 
nm, D 50: 920 nm, D 90: 2.74 µm with span value 2.55) (Figure 2 B) was found to be slightly 
lower than NMP prepared without mannitol (D 10: 409 nm, D 50: 1007 nm, D 90: 3.55 µm 
with span value 2.92) (Figure 2 A). Formulations containing mannitol with PVA as an 
osmotic agent exhibited improved drug encapsulation (from 59.85% to 72.8%). A NMP 
loading of VD3 of 133 ± 24 µg/mg was achieved with mannitol. Here, the single emulsion 
was prepared at higher speed (18,000 rpm) to get broader particle sizes with high span value. 
This wider particle size distribution was a prerequisite to achieving tightly packed particles in 
MN tips as discussed further later. The PLGA NMP exhibited a negative zeta-potential of -
27.2 ± 0.69 mV.  
3.2 In-vitro release study 
Real-time drug release kinetics of VD3 from PLGA NMP exhibited a typical tri-phasic release 
profile up to 5 days, as shown in Figure 3. An initial burst release followed by a slower 
release can be observed. Finally, a third release phase was observed, due to the broad particle 
size distribution from nano- to micron size of PLGA particles. The PLGA NMP prepared in 
the presence of mannitol showed a slightly lower initial burst release compared to the PLGA 
microspheres prepared alone in PVA solutions. Mannitol acts as an osmotic, agent giving a 
less porous NMP structure. Hence, we observed that mannitol-added NMP showed a drug 
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release of over 13% at the first hour, whereas the NMP batch without the addition of 
mannitol showed 22 % drug release. As the initial burst release is governed by a diffusion 
mechanism, less porous NMP structure prepared with mannitol gives lower diffusion-based 
burst release.   
3.3 Characteristics of PLGA NMP loaded PVP MN arrays 
The digital microscopic images (Figure 4) clearly showed NMP specifically concentrated at 
the tips (white in colour) of MN arrays. Accumulation of NMP in the MN tips was due to the 
high density of PLGA particles (1.3g/cm3) [26] and the use of high-speed centrifugation 
during MN preparation. The resulting needles measured 600 μm in height with PLGA 
particle concentrated sharp tips tapering to a 20 μm radius of curvature that encapsulated 265 
± 32 µg (n=3) of VD3 per patch (0.49cm
2 size). Heights of bilayer MN with PLGA NMP 
were customised by different weight ratios of NMP to PVP polymer gel, as shown in Figure 
5. As particle size is a vitally-important stability parameter for NMP, particle size was 
measured before and after MN preparation. The PLGA NMP embedded bilayer MN was 
dissolved in PBS pH 7.4 buffer without any changes in particle size or observation of 
aggregation. The average particle size remained similar before and after making MN, as 
shown in Table 2. Here, the dried state of the polymer matrix of MN possibly acts as a 
stabiliser for NMP particle size.  
3.4 Scanning Electron Microscopy 
To further characterise the MN, the structures were examined using SEM (Figure 6). SEM 
images showed NMP specifically concentrated in MN tips and compactly packed. The 
different particle sizes from nano to micron size level in addition to the presence of adhesive 
PVP polymer gave a compactly packed structure to the arrays. The tips of bilayer MNs were 
packed with PLGA NMP with a porous structure. There was a discrete line between PLGA 
NMP mixed with PVP polymer and plain PVP polymeric matrix clearly visible (figure 6.Ai). 
There was a porous and rough texture at the tips of MN containing PLGA particles, while a 
smoother texture was exhibited by the unloaded PVP microneedles. These topographies could 
reﬂect different arrangements of the incorporated PLGA particles within the matrix of PVP 
polymer. To study the structure of the interior of tips of the MN, they were broken and then 
visualised by SEM. We found that the interior of the tips of the MN was also completely and 
compactly filled with PLGA particles in the PVP matrix.  (Figure. 6B). Microparticles and 
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nanoparticles were spherical with a similar size measured by SEM as that measured using the 
particle sizer. 
3.5 Mechanical strength and Parafilm insertion of MN arrays 
Following application of the axial load, the bilayer MN showed a 10.77% height reduction 
(Figure 7B). The mechanical strength of MN arrays was found to be strong enough to bear 32 
N force used for skin and Parafilm M® insertion. The same force of 32 N was applied to 
assess the effects of insertion on needle height, using Paraﬁlm M® as an artiﬁcial membrane 
to mimic the skin [26].  It was found that NMP loaded bilayer MN penetrated to the third 
layer of Parafilm M® (Figure 7A). Considering the thickness of each layer of the Parafilm M® 
membrane (127 µm), the insertion depth could be measured up to 381 µm which relates to 
more than 60% of the needle height inserted.  
3.6 Determination of skin penetration  
A non-invasive optical imaging technique, OCT, was used to acquire real-time images of the 
insertion of the bilayer dissolving MN patches in the neonatal porcine skin and Parafilm M® 
layers. The two-dimensional side-view of bilayer MNs inserted into the porcine skin are 
shown in Figure 8B. Bilayer MN patches possessed the capability to be inserted into neonatal 
porcine skin, reaching insertion depths of approximately 250–300 μm.  In the case of 
Parafilm M®, it was penetrated down to the third layer (approximately 370 μm), as shown in 
Figure 8A.  This is very similar to previous insertion studies of polymeric MN into Paraﬁlm 
M® [27]. 
3.7 Ex-vivo deposition studies in excised porcine skin 
Deposition of VD3 across neonatal porcine skin was signiﬁcantly enhanced by using bilayer 
MN arrays in comparison with the control set-up (p < 0.05) (Figure 9). As can be seen in the 
drug permeation profile, drug concentration increased with skin depth, until reaching a 
maximum at a depth of 0.4 mm (171.7 ± 7.39µg/cm2). The concentration of VD3 in deeper 
layers of the skin (depths between 0.4 mm and 1.4 mm) was lower. Negligible in-skin drug 
concentrations in the case of control VD3-NMP loaded patch films were found. Considering 
the cumulative concentration of VD3 in the skin after MN insertion, 74.2 ± 9.18% (196.6 ± 
24.3 µg) of VD3 of the initial amount of the drug present in the array was administered. These 
results are in close agreement with the insertion studies described previously [28]. Therefore, 
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the results demonstrate the bilayer PVP-based dissolving MN arrays significantly assist the 
delivery of the drug particles into skin. Such particles may then sustain delivery long after the 
MN patches are removed from skin. 
 
Discussion 
MN technology has been used to enhance skin permeability to nanoparticles and 
microparticles. Several studies can be found in the literature describing MN-assisted 
permeation of nano- and micro-metric particles [29]. PLGA- and PLA-based biodegradable 
MN were prepared for controlled and/or targeted skin delivery. These polymers are well 
explored and extensively characterised for targeted and controlled drug delivery because of 
the biodegradable nature of PLGA. Tailored drug release can be achieved based on its 
molecular weight and lactide: glycolide ratio [30]. However, the formulation process requires 
the use of organic solvents and/or elevated temperatures that can damage biomolecule 
stability [31]. Besides, it is difficult to load high doses of drug or drug-loaded particles in MN 
tips. Some researchers have performed multiple steps to concentrate the particles in the 
needle tips [32]. To construct MN arrays capable of rapid delivery of drug-loaded PLGA 
particulate cargos, we developed bilayer MN to deposit PLGA NMP into the viable layers of 
the skin upon the aqueous dissolution of a supportive PVP polymer matrix. The proposed 
method to concentrate the NMP in the MN tips only required a single centrifugation step. 
Using this technique, it is possible to concentrate the drug-loaded polymeric particles into the 
MN tips for intradermal delivery without wastage of drug. We postulated that such a platform 
would provide rapid administration through short time MN application, while facilitating 
combined bolus and long-term dosing of cargos released from cutaneous implantation of 
PLGA nano- and microparticulate depots, respectively.   
VD3 was selected as a model drug to prove this concept with PLGA NMP. This molecule is 
hydrophobic and potent. These two characteristics make this drug an ideal candidate for this 
study, as it can be easily encapsulated in hydrophobic PLGA nanoparticles. The potency of 
the drug is important because the drug loading in the MN arrays is limited, as the drug is 
encapsulated inside NMP and subsequently incorporated into the needle tips. 
Firstly, VD3 loaded PLGA NMP were prepared and characterized for particle size and 
encapsulation. The release kinetics of the drug from the PLGA particles was evaluated as the 
drug can be released in different ways based on the particle size [33].  In-vitro release kinetics 
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of VD3 from PLGA NMP exhibited a typical tri-phasic release profile. A tri-phasic release 
phenomenon has been found when a lag release period occurs after the initial burst from 
nanoparticles and the surfaces of microparticles and until polymer degradation starts in the 
microparticles. Therefore, the combined range of nano and micron size particles is used here 
as an advantage to tailor immediate and then sustained drug release, respectively. 
PVP was selected as the mechanical and structural material for dissolving MN with PLGA 
NMP, as it exhibits high water solubility with good mechanical strength and is biocompatible 
[34, 35]. Concentrated PLGA particles at the tips of MN arrays remained together because of 
the very good adhesive properties of the PVP polymer. Moreover, this type of MN array 
could be prepared successfully using different micromould shapes, like pyramidal and conical 
shapes (Figures 4 and 6). PLGA NMP preparation was carried out in a PVA solution because 
of its surfactant and stabiliser effects during the single emulsion solvent evaporation method. 
PVA is a well-established polymeric surfactant for PLGA nanoparticle and microparticle 
preparation [36].  The prepared PLGA NMP prepared with PVA were directly mixed with 
PVP gels for MN preparation. Here, advantageously, there was no need to dry the NMP by 
lyophilisation before MN formulation. MN prepared from pure PVP were brittle in nature 
[20] and low molecular weight PVA acted as a softening agent to yield good mechanical 
properties in PVP MN.  
Herein, the wider particle size distribution of NMP as shown in Figure 3 and Table 1 was 
advantageously used to achieve compact packaging of NMP into MN tips (similar to the 
sand-pebble mixture in the bottle to fill it completely without any voids). It was quite possible 
to preferentially accumulate PLGA NMP in tips because of the high density of PLGA 
particles and the high centrifugation force, as depicted in SEM images in Figure 6. 
Concentrating the drug particles in the MN tips in this way will, in all, likelihood improve the 
efficiency of particle deposition in the viable skin layers upon insertion. 
As illustrated in the Graphical Abstract, the rationale behind this system is to enable targeted 
delivery of VD3-loaded NMP into selected tissues of the skin using soluble PVP MNs. The 
extracellular ﬂuid of the epidermis and dermis allow dissolution of MN, followed by slow 
degradation of PLGA, thereby providing sustained delivery of VD3. This slow release of VD3 
in the epidermis and dermis may mimic the natural sunlight-based VD3 biosynthesis. Ex-vivo 
deposition studies showed enhanced administration compared to control patches without MN. 
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VD3 has been successfully formulated and administrated transdermally and subcutaneously 
by using different vehicles, including nanocarriers [37-39]. However, our proposed system 
presents a potential advantage, which is reduction of the administration frequency. In this 
case, the administration of the MN arrays delivers the vitamin-loaded NMP inside the skin. 
Subsequently, the particles provide a slow and prolonged release of the molecule over time, 
thus potentially reducing the frequency of VD3 administration.  
This research work showed an alternative method to prepare and administer PLGA 
particulate systems with MN-based minimally invasive technology. MN arrays loaded with 
concentrated NMP allows targeting to the deeper layers of skin for sustained delivery. It is 
possible that, customisation of molecular weight of polymers and size of particles will permit 
tailored delivery profiles of molecules based on their desired pharmacological effect. 
Currently, more than 12 marketed products based on microparticle-based depots of potent 
molecules exist. These completely rely on subcutaneous or intramuscular injections in 
clinical setting while MN arrays can be easily self-administered by the patient [40-42]. This 
type of technology shows potential to be used to sustain delivery of drugs to patients without 
the use of hypodermic needles and intervention of healthcare professionals. Further studies 
should now be conducted to evaluate the in vivo efficacy of this system. Following this, work 
on scaled-up manufacture and development of the larger patch sizes required for successful 
human dosing will be the vital next steps in translation. 
5. Conclusions 
This study demonstrated a model drug loaded PLGA NMP which specifically was 
concentrated at the tips of MN arrays to form bilayer dissolving MN structures by a simple 
centrifugation technique that is commonly used for MN preparation. It was demonstrated that 
biodegradable nano-microparticles embedded bilayer MN arrays significantly assist skin 
deposition. These proof-of-concept findings may address the long-standing question of 
effectively delivering the nanoparticles and microparticles to the viable skin (epidermis and 
dermis) layers for maximum therapeutic gain and patient compliance.  
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Figure Legends. 
Fig. 1. Schematic representation of fabrication of PLGA nano-microparticle-loaded bilayer 
microneedle arrays. 
Fig. 2. Particle size and particle size distribution of VD3-loaded PLGA NMP preparation (A) 
without 5% w/w mannitol and (B) with 5% w/w mannitol. Redline (-) indicates the bimodal 
distribution of particle size from nano- to micron size.  
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Fig. 3.  In-vitro release study of VD3 from PLGA NMP prepared with and without 5% w/w 
mannitol (Means ±S.D., n =3). 
Fig. 4.  Digital microscopic images of PLGA NMP-loaded bilayer microneedles. (A) Conical 
MN arrays (19×19). (B) Conical arrays (12×12). (C) Pyramidal (14×14) arrays. 
Fig. 5. Customisation of the height of bilayer structure of microneedle arrays based on the 
different ratio of NMP and microneedle-forming polymer (PVP). Digital microscopic images 
of MN prepared from the different weight ratios of NMP and PVP. (A) 1:1, (B) 1:1.5, (C) 
1:2, (D) 1:2.5 and (E) 3D graph based on calculated heights of bilayer structure with different 
weight ratios of NMP and PVP. The needle heights are the average obtained after measuring 
at least 10 needles per array in 4 different MN arrays. 
Fig. 6. Scanning electron micrograph of PLGA NMP-loaded bilayer microneedles: (A) 
Single array images of conical microneedles; i) Single needles from 19×19 arrays; ii) Single 
needles from 12×12 arrays. (B) Cross section of a single needle of : i) 19×19 arrays ii) 12×12 
arrays and  (C) i) Microneedles from pyramidal arrays ii) Single needle from pyramidal 
arrays. 
Fig.7. Percentage of holes created in each Paraﬁlm M® layer and their corresponding 
insertion depth, using an insertion force of 32 N for bilayer microneedles (conical) arrays 
(means ± S.D., n = 3) (A). Percentage reduction in height of MN (conical) upon exertion a 
force of 32 N at 1.19 m/s, held for 30 s (means ± S.D., n = 3) (B). 
Fig. 8. Optical coherence tomography images after insertion of drug-loaded PLGA NMP 
embedded bilayer microneedle arrays into (A) 8 layers of Parafilm M® (B) full thickness 
neonatal porcine skin. The dashed line represents the surface of the Parafilm M® /skin. 
Fig. 9.  The concentration of VD3 in different depths of excised neonatal porcine skin 
following the application of control patches and bilayer microneedles containing VD3-loaded 
PLGA NMP. Results represent means ± S.D., n =3. 
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Tables  
 
Table 1 Different ratios of PLGA NMP and 20% PVP solution for microneedle 
formulation. 
Wt Ratio of NMP : 
PVP 
1:1 1:1.5 1:2 1:2.5 
Solution of NMP 3gm 1gm 1gm 1gm 
20% PVP solution 3gm 1.5gm 2gm 2.5gm 
 
 
Table 2 Particle size and span value of VD3 loaded PLGA NMP before and after MN 
formulation 
Parameter 
Particle Size  
D(0.1) D(0.5) D(0.9) 
Vol. Weighted 
Mean D[4, 3]  
Span Value 
Before MN 286nm  833 nm 2.73 µm  1040nm 2.863  
After MN 338nm  843 nm 3.00µm  1095nm 3.156 
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